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and 1.90.4 cm2; and gradient of 8.13.3 mmHg and 7.63.1 mmHg, at
30 days and 6 months, respectively. Compared with baseline, 76.3% of
patients experienced improvement in NYHA class at 30 days, and
84.9% at 6 months. Permanent pacemaker rates were 11.7% at 30 days,
and 13.4% at 6 months.
CONCLUSIONS The Evolut R TAV is associated with exceptional
safety at 30 days, which continued at 6 months. We plan to report 1-
year outcomes at the time of the meeting.
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BACKGROUND Data on transcatheter aortic valve replacement
(TAVR) failure is limited. The study objective was to determine the
incidence, timing, clinical characteristics and treatment outcomes of
patients diagnosed with TAVR failure attributed to transcatheter heart
valve (THV) thrombosis.
METHODS A retrospective analysis of prospectively raised data
included in a single center TAVR registry. Patients in this 100% follow-
up registry have a predeﬁned echocardiographic and clinical follow-
up schedule (1 month, 6 months,1 year and yearly thereafter or earlier
if symptomatic). THV thrombosis was deﬁned as (1) valve dysfunction
(mean transvalvular gradient >20 mmHg, reduction of the aortic valve
area to <1.2 cm2 or new onset more than mild transvalvular regurgi-
tation) secondary to thrombosis diagnosed based on response to
anticoagulation therapy or typical ﬁndings on imaging modality
(Echo/CT) or (2)mobile mass suspicious of thrombus detected on the
valve, irrespective of dysfunction, and in the absence of infection. The
primary study endpoint was the incidence of THV thrombosis.
RESULTS During the study period (September 2007-March 2015), 588
patients underwent TAVR (CoreValve-305, Sapien XT-124,Sapien 3-
117,Lotus-40,others-2). THV thrombosis was diagnosed in 12(2%) pa-
tients: Sapien XT-9, Sapien3-1 and Lotus-2. Thrombosis was not
observed in any of the CoreValve patients. The mean age was
798years and the majority were females (n¼10, 83.3%). The median
time to thrombosis detection was 180 days(interquartile range, IQR 23-
472). 3 patients were diagnosed early (within 1 month) after TAVR, of
which 2 had a Lotus valve. In another 3 patients, thrombosis was
diagnosed late (>1 year after TAVR). Half of the patients had no wors-
ening symptoms at the time of diagnosis. In symptomatic subjects,
exertional dyspnea with change in NYHA class was the most common
mode of presentation (n¼5). 1 patient presented with stroke. Treatment
at the time of detection of thrombosis was dual antiplatelet therapy in
11 and aspirin monotherapy in 1. No cases of THV thrombosis were seen
in patients discharged on oral anticoagulation. Mean aortic valve
pressure gradient was elevated in 10(83%) of thrombosis patients; mean
transvalvular gradient for all subjects being 3616mmHg. Other echo-
cardiographic ﬁndings included thrombotic mass on the leaﬂets (n¼7,
58.3%) and thickening of leaﬂets with reduced mobility. Median serum
NT-proBNP level was 1318 pg/ml (IQR 1123-1605). After treatment with
anticoagulants, mean aortic gradient and NT-proBNP levels reduced
signiﬁcantly. There were no deaths related to valve thrombosis.
CONCLUSIONS THV thrombosis is a rare but an important cause of
TAVR failure, most frequently detected at a median of 180 days after
the procedure. Patients may present with exertional dyspnoea and/orincreased transvalvular gradients. Anticoagulation is effective in
improving gradients and clinical status. Optimal antithrombotic
therapies after TAVR need to be deﬁned, and randomized controlled
trials are needed.
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BACKGROUND End stage renal disease (ESRD) poses unique chal-
lenges in the treatment of patients with severe aortic stenosis. While
surgical valve replacement in patients with ESRD has been associated
with an increase in the risk of morbidity and mortality, the results
from transcatheter valve replacement have not been clearly deﬁned.
METHODS The CoreValve US Expanded Use Study is a prospective,
nonrandomized trial of transcatheter aortic valve replacement (TAVR)
in extreme risk (ER) patients with ESRD or other speciﬁc comorbidities
excluding them from the Pivotal Trial. Patients with ESRD who were
deemed to be ER by two surgeons, had symptoms attributable to
aortic stenosis, had an aortic valve area of 0.8 cm2 (or aortic valve
area index  0.5 cm2), and either a mean gradient 40 mmHg or peak
velocity  4.0 m/s with one year of follow up are included in this
report. The primary endpoint for the study was all-cause mortality or
major stroke at 12 months. One year outcomes are compared with
patients enrolled in the CoreValve ER US Pivotal Trial and an objective
performance goal (OPG) pre-speciﬁed for the ER US Pivotal Trial.
RESULTS Fifty-four patients with ESRD underwent TAVR with Cor-
eValve as part of the US Expanded Use Study and have reached one year
follow up. Mean STS-PROM was 17.1  8.4 in ESRD patients versus 10.3
 5.5 in ER US Pivotal patients. The rate of all-cause mortality or major
stroke at 12 months was 26% in the ER US Pivotal Trial, 35% in the ESRD
Expanded Use Study, and compared with 43% which is the ER US
Pivotal Objective Performance Goal. Initial 30 day all-cause mortality
was 7.4% (8.4 % in US Pivotal) and 1 year was 35.2% in ESRD patients.
Any stroke or TIA at 1 year was 1.9%, major vascular injury was 3.7% and
new permanent pacemaker rate was 22.9%. Valve performance at one
year was comparable to post-procedure in effective oriﬁce area (1.82
cm2 post-procedure v. 1.81 cm2 1 year) and mean gradient (9.8 mmHg
post-procedure v. 9.2mmHg 1 year).
CONCLUSIONS Early mortality in patients with ESRD is comparable to
ER patients without ESRD but one year data suggest a higher mortality
likely due to comorbid conditions. Stroke and major vascular injury
were infrequent and valve durability is maintained at one year.
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BACKGROUND A peri-procedural stroke rate of 2-7% remains a major
complication after transcatheter aortic valve replacement (TAVR) and
